Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
HIV InfectionHyperlipidemia
Interventions
DRUG

Atazanavir

atazanavir 400 mg once daily

DRUG

current antiretroviral regimen

Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus \> 2 NRTIs

Trial Locations (7)

45267

University of Cincinnati, Cincinnati

46202

Indiana University, Indianapolis

53792

University of Wisconsin, Madison

60611

Northwestern Universtiy, Chicago

92103

University of California, San Diego

Unknown

ACLIRES - Argentina S.R.L., Buenos Aires

Universita degli studi di Modena e Reggio Emilia, Modena

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Northwestern University

OTHER

NCT00225017 - Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study | Biotech Hunter | Biotech Hunter